Immunotherapy of Cancer An Innovative Treatment Comes of Age /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Yamaguchi, Yoshiyuki (Επιμελητής έκδοσης)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Tokyo : Springer Japan : Imprint: Springer, 2016.
• Έκδοση: 1st ed. 2016.
• Θέματα: Medicine.; Cancer research.; Immunology.; Oncology.; Medicine & Public Health.; Cancer Research.

This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recogn...

Πίνακας περιεχομένων:

• Part I Overview, History, Classification
• Chapter 1 Overview of Current Cancer Immunotherapy
• Part II BRMs and Crude Agents
• Chapter 2 Bacterial Preparations
• Chapter 3 Polysaccharides
• Chapter 4 BCG
• Part III Cytokines
• Chapter 5 αβ-T Cells
• Chapter 6 NKT Cell-Based Immunotherapy
• Chapter 7 Natural Killer Cells
• Chapter 8 γδ T Cell-Based Cancer Immunotherapy
• Chapter 9 Genetically engineered T cells
• Part IV Vaccine Therapy
• Chapter 10 Peptide Vaccine
• Chapter 11 Personalized Peptide Vaccine
• Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies
• Chapter 13 Protein vaccine
• Chapter 14 Dendritic Cell-Based Vaccine for Cancer
• Part V Immunoadjuvants
• Chapter 15 CpG Motif
• Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy
• Chapter 17 Novel Adjuvants
• Part VI Immunocheckpoints
• Chapter 18 Anti-CTLA-4 Ab
• Chapter 19 Anti-PD-1, PD-L1 Ab
• Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals
• Part VII Regulation of Immunosuppression
• Chapter 21 Regulatory T Cells
• Chapter 22 MDSC: Myeloid-Derived Suppressor Cells
• Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials
• Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials
• Part IX Personalized Immunotherapy
• Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy.